2023
DOI: 10.1021/jacs.2c09967
|View full text |Cite
|
Sign up to set email alerts
|

Defect-Rich Glassy IrTe2 with Dual Enzyme-Mimic Activities for Sono-Photosynergistic-Enhanced Oncotherapy

Abstract: The complexity, diversity, and heterogeneity of malignant tumors pose a formidable challenge for antitumor therapy. To achieve the goal of significantly enhancing the antitumor effect, nanomedicine-based synergistic therapy is one of the important strategies. Herein, we innovatively report a defect-rich glassy IrTe2 (G-IrTe2) with weak Ir–Te bond strength for synergistic sonodynamic therapy (SDT), chemodynamic therapy (CDT), and mild photothermal therapy (PTT). G-IrTe2 sonosensitizer under ultrasound (US) stim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
19
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 45 publications
(19 citation statements)
references
References 38 publications
0
19
0
Order By: Relevance
“…On the one hand, ST can reduce the internal glucose of tumors and reduce the energy source of tumor cells. CAT and CAT-like activity Au-rGO-ZnO@PVP, PMR, PEBVO@PEGNRS, Bac@ARS, SPNC, PB+Ce6@Hy, Ce6-MnO 2 -PVs, YHM, Cu 2 O-CNX@CeO 2 , CAT@HA-HMME NPs [51,53,54,156,157,158,159,160,161,162] Consumption of GSH AIMP [163] Catalytic CDT Mn 3 O 4 /OCN-PPIX@BSA, G-IrTe 2 [164,165] Suppress GSH generation BMP-BSO [166] Consumption of GSH, catalytic CDT UPFB, mZMD NCs, MO@FHO, AIPH@Cu-MOF [52,55,84,85] Consumption of GSH, catalytic ST CPCs@PEG [167] Reverse immunosuppression HABT-C@HA, MFC [168,169] Catalytic ST PPGE NCs [50] Consumption of GSH, catalytic CDT, catalytic ST MPG [170] pH-response DOX@PCN-224/Pt NPs [171] Carry oxygen Reverse immunosuppression TL@HPN(PAI/USI), DMXAAS [172,173] ICG-DOX NPs/PFH@SP94-Lip, SAFE [174,175] Autogeneration of oxygen Chl (MChl) [176] Reduce HIF-1𝛼 M@C [73] Reduce HIF-1𝛼 Relieve hypoxia P-BTO [71] IR780@INPS-CTX, IRP-NPs [177,178] Hypoxia-response ZTC, MCA, C-TiO 2 /TPZ@CM [77,179,180] Catalytic CDT Cu-MOF NPs [75] CAT activity hMVS [78] On the other hand, the produced H 2 O 2 can be used as the substrate of CDT and catalase to catalyze the formation of ROS and oxygen. [56]…”
Section: Tme and Tme-related Sdtmentioning
confidence: 99%
“…On the one hand, ST can reduce the internal glucose of tumors and reduce the energy source of tumor cells. CAT and CAT-like activity Au-rGO-ZnO@PVP, PMR, PEBVO@PEGNRS, Bac@ARS, SPNC, PB+Ce6@Hy, Ce6-MnO 2 -PVs, YHM, Cu 2 O-CNX@CeO 2 , CAT@HA-HMME NPs [51,53,54,156,157,158,159,160,161,162] Consumption of GSH AIMP [163] Catalytic CDT Mn 3 O 4 /OCN-PPIX@BSA, G-IrTe 2 [164,165] Suppress GSH generation BMP-BSO [166] Consumption of GSH, catalytic CDT UPFB, mZMD NCs, MO@FHO, AIPH@Cu-MOF [52,55,84,85] Consumption of GSH, catalytic ST CPCs@PEG [167] Reverse immunosuppression HABT-C@HA, MFC [168,169] Catalytic ST PPGE NCs [50] Consumption of GSH, catalytic CDT, catalytic ST MPG [170] pH-response DOX@PCN-224/Pt NPs [171] Carry oxygen Reverse immunosuppression TL@HPN(PAI/USI), DMXAAS [172,173] ICG-DOX NPs/PFH@SP94-Lip, SAFE [174,175] Autogeneration of oxygen Chl (MChl) [176] Reduce HIF-1𝛼 M@C [73] Reduce HIF-1𝛼 Relieve hypoxia P-BTO [71] IR780@INPS-CTX, IRP-NPs [177,178] Hypoxia-response ZTC, MCA, C-TiO 2 /TPZ@CM [77,179,180] Catalytic CDT Cu-MOF NPs [75] CAT activity hMVS [78] On the other hand, the produced H 2 O 2 can be used as the substrate of CDT and catalase to catalyze the formation of ROS and oxygen. [56]…”
Section: Tme and Tme-related Sdtmentioning
confidence: 99%
“…[6][7][8][9][10] To boost the therapeutic effect of PTT, researchers are working on the development of various PTAs, including inorganic and organic ones. [11][12][13][14][15][16] Compared with inorganic ones, organic PTAs are featured with the merits of good biocompatibility and flexibility for structure design and modulating light absorption, thus becoming ideal alternatives for PTT. [17][18][19] To increase the penetration depth of laser and improve the PTT effect of PTAs, intense absorption in the near-infrared (NIR) region and high photothermal conversion efficiency (PCE) are desirable.…”
Section: Introductionmentioning
confidence: 99%
“…[ 6–10 ] To boost the therapeutic effect of PTT, researchers are working on the development of various PTAs, including inorganic and organic ones. [ 11–16 ] Compared with inorganic ones, organic PTAs are featured with the merits of good biocompatibility and flexibility for structure design and modulating light absorption, thus becoming ideal alternatives for PTT. [ 17–19 ]…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, in addition to early diagnosis, efficient and accurate treatment still remains an important problem to be solved. , With the rapid development of nanoscience, many noninvasive therapeutic methods based on nanomedicine have been developed . Among these, cytotoxic reactive oxygen species (ROS)-mediated nanodynamic therapy can induce irreversible cellular oxidative damage and apoptosis and has drawn much attention as an advanced therapeutic modality. For instance, photodynamic therapy (PDT) is a noninvasive and spatiotemporally controllable therapy that produces ROS upon irradiation of photosensitizers with near-infrared (NIR) light in the presence of oxygen. , However, the poor penetration depth significantly limits the application of PDT, especially for deep-seated tumors . Recently developed sonodynamic therapy (SDT) is another noninvasive treatment modality that uses ultrasound (US) to activate sonosensitizers to interact with the surrounding oxygen and produce highly cytotoxic ROS to induce apoptosis .…”
Section: Introductionmentioning
confidence: 99%